U.S. FDA approves Novartis' leukemia treatment

(Reuters) – The U.S. Food and Drug Administration approved Novartis AG’s Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *